Microbiota γ‐Butyrobetaine Is Associated With Increased Risk of Major Adverse Limb Events in People With Lower Extremity Arterial Disease Undergoing Endovascular Therapy
Journal of the American Heart Association · 19.08.2025 · 14 (16)
DOI: 10.1161/jaha.124.037356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 19.08.2025. Verfasst von Zheng-Wei Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine National Taiwan University College of Medicine and Hospital Taipei Taiwan. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Endovascular Procedures, Betaine, Lower Extremity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Peripheral artery disease (PAD), a significant contributor to both acute and chronic illnesses, indicates a grave prognosis, but it is often unrecognized and receives inadequate treatment. γ‐Butyrobetaine, formed during gut microbial metabolism of L‐carnitine, acts as a proatherogenic intermediate in the production of trimethylamine N ‐oxide (TMAO). While TMAO has been linked to a heightened risk of cardiovascular mortality of individuals with PAD, the impact of γ‐butyrobetaine remains unclear. The objective of this study was to examine the prognostic value of serum γ‐butyrobetaine for patients with PAD.
Methods
We prospectively enrolled 395 patients with symptomatic PAD. Comprehensive medical histories, encompassing demographic and medication data, were collected, and serum biochemistry data, including TMAO and γ‐butyrobetaine, were obtained. These patients, with a mean age of 72.2 years (61% men), were followed for an average of 1.5 years. They were categorized into 2 groups: 165 patients with intermittent claudication and 230 patients with critical limb‐threatening ischemia. The primary outcome studied was major adverse limb events (MALE), which included lower‐limb revascularization and amputation. MALE developed in 89 (22.5%) patients. Following adjustment for confounding factors in the multivariate Cox proportional hazards model, γ‐butyrobetaine was significantly associated with MALE (hazard ratio, 1.93 [95% CI, 1.35–2.76]). By contrast, TMAO did not show a significant association with the risk of MALE.
Conclusions
While both TMAO and γ‐butyrobetaine were linked to increased major adverse cardiovascular events in patients with PAD, only γ‐butyrobetaine was associated with an elevated risk of MALE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine National Taiwan University College of Medicine and Hospital Taipei Taiwan.
- Division of Cardiology, Department of Internal Medicine National Taiwan University College of Medicine and Hospital Dou-Liu Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University Taipei Taiwan.
- Cardiovascular Center National Taiwan University Hospital Taipei Taiwan.
- Department of Medical Research National Taiwan University Hospital Taipei Taiwan.
- Bachelor Program of Biotechnology and Food Nutrition National Taiwan University Taipei Taiwan.
ORCID-Profile: Zheng-Wei Chen, Wei-Kai Wu, Jiun-Yang Chiang, Jen-Kuang Lee, Ming-Shiang Wu
Zitieren
APA
Chen, Z. W., Wu, W. K., Chiang, J. Y., Cheng, N. C., Lee, J. K., & Wu, M. S. (2025). Microbiota γ‐Butyrobetaine Is Associated With Increased Risk of Major Adverse Limb Events in People With Lower Extremity Arterial Disease Undergoing Endovascular Therapy. Journal of the American Heart Association, 14(16). https://doi.org/10.1161/jaha.124.037356
Vancouver
Chen ZW, Wu WK, Chiang JY, Cheng NC, Lee JK, Wu MS. Microbiota γ‐Butyrobetaine Is Associated With Increased Risk of Major Adverse Limb Events in People With Lower Extremity Arterial Disease Undergoing Endovascular Therapy. Journal of the American Heart Association. 2025;14(16). doi:10.1161/jaha.124.037356
BibTeX
@article{Chen2025,
author = {Chen, Zheng-Wei and Wu, Wei-Kai and Chiang, Jiun-Yang and Cheng, Nai-Chen and Lee, Jen-Kuang and Wu, Ming-Shiang},
title = {Microbiota γ‐Butyrobetaine Is Associated With Increased Risk of Major Adverse Limb Events in People With Lower Extremity Arterial Disease Undergoing Endovascular Therapy},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {16},
doi = {10.1161/jaha.124.037356}
}
EUVIMED